Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference

DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (the Company or Novan) (Nasdaq: NOVN), today announced that data from the Companys completed Phase 2 and Phase 3 clinical studies of berdazimer 10.3% gel (previously referred to as SB206) for molluscum contagiosum will be presented at the 2022 Winter Clinical Dermatology Conference, being held January 14-19, 2022, in Koloa, Hawaii.